<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31940">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090218</url>
  </required_header>
  <id_info>
    <org_study_id>2013/984/REK-Vest.</org_study_id>
    <nct_id>NCT02090218</nct_id>
  </id_info>
  <brief_title>I-Gel in Out-of-hospital Cardiac Arrest in Norway</brief_title>
  <acronym>I-CAN</acronym>
  <official_title>I-Gel Versus Current Practice in Out-of-hospital Cardiac Arrest by Paramedics in Norway - a Prospective Stepped Wedge Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Midt-Norge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Førde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to compare the effectiveness of a newer supraglottic
      airway method (the i-Gel), compared to current airway management practice in out-of-hospital
      cardiac arrests treated by Norwegian ambulance services.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ventilation success</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ventilation success defined as successful insertion of device with visible chest movement with each ventilation, audible air passage on auscultation, and ETCO2 confirmation (if available) of tube placement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival to hospital discharge / 30-day survival</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of ETCO2 related to the presence and quality of bystander CPR</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral function assessed by Glascow Outcome Score at discharge from hospital</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insertion related complications</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Out of Hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>I-Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I-Gel supraglottic airway device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTS, ETI or other airway practice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laryngeal tube, endotracheal tube or other current airway management practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-Gel</intervention_name>
    <description>I-Gel supraglottic airway device</description>
    <arm_group_label>I-Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LTS, ETI or current airway management practice</intervention_name>
    <description>Laryngeal tube, endotracheal tube, bag-mask-ventilation</description>
    <arm_group_label>LTS, ETI or other airway practice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-of-hospital cardiac arrest patients requiring and receiving advanced airway
             management on ambulance missions. Advanced airway management is defined as the
             attempted insertion of an airway adjunct (I-Gel, laryngeal tube or ETI) or the
             administration of ventilatory assistance/support (including bag-mask ventilation
             (BMV) or other ventilatory support.

          -  Adult patients (&gt; 18 years).

        Exclusion Criteria:

          -  Non-adult patients / minors (&lt; 18 years).

          -  Traumatic cardiac arrest.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geir A Sunde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon-Kenneth Heltne, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guttorm Brattebø, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanne Klausen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geir A Sunde, MD</last_name>
    <phone>+47 55975000</phone>
    <email>gasu@helse-bergen.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sorlandet Sykehus</name>
      <address>
        <city>Arendal</city>
        <zip>4838</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Jacobsen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lars Jacobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geir A Sunde, MD</last_name>
      <phone>+47 55975000</phone>
      <email>gasu@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Geir A Sunde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innlandet Sykehus HF</name>
      <address>
        <city>Brumunddal</city>
        <zip>2381</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dag F Kjernlie, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Terje Ødegården</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dag F Kjernlie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terje Ødegården</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mari Bjørnhaug</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde HF</name>
      <address>
        <city>Førde</city>
        <zip>6800</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Marcinkowski</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Marcinkowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Fonna HF</name>
      <address>
        <city>Haugesund</city>
        <zip>5504</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alf Reksten, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alf Reksten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tommy Tjøsvoll</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssykehus</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olav Østebø</last_name>
    </contact>
    <contact_backup>
      <last_name>Paul Vindelev</last_name>
    </contact_backup>
    <investigator>
      <last_name>Olav Østebø</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Vindelev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ambulanse Midt-Norge HF</name>
      <address>
        <city>Trondheim</city>
        <zip>7502</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin E Bakkelund, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sigurd Heian, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karin E Bakkelund, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sigurd Heian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
